sasha12kapoor
10+ Views

Particle Therapy Market : Technological advancements in the field of Heavy Ion Therapy

According to the new market research report Particle Therapy Market by Type (Heavy Ion, Proton Therapy), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate, Breast), Application (Treatment, Research) – Forecast to 2023“, published by MarketsandMarkets™, the global Particle Therapy Market is projected to reach USD 1,349 million by 2023 from USD 865 million in 2018, at a CAGR of 9.3%.
Browse in-depth TOC on “Particle Therapy Market“
80 – Tables
36 – Figures
138 – Pages

The major factors driving the growth of the Particle Therapy Market are the growing global prevalence of cancer, growing adoption of particle therapy in clinical trials, advantages offered by particle therapy over photon therapy, and the increasing number of particle therapy centers worldwide.
The pediatric cancer segment is expected to account for the largest share of the Particle Therapy Market, by cancer type, in 2018
Based on cancer type, the Particle Therapy Market is segmented into pediatric cancer, prostate cancer, breast cancer, lung cancer, head & neck cancer, and other cancers. The pediatric cancer segment is expected to account for the largest share of the Particle Therapy Market in 2018. The growing incidence of pediatric cancer and the high success rates and minimal long-term risks achieved with particle therapy are the major factors driving the growth of this market segment.
Research applications to register the highest CAGR in the global Particle Therapy Market during the forecast period
Based on applications, the Particle Therapy Market is segmented into treatment applications and research applications. The research applications segment is expected to witness the highest CAGR during the forecast period. Growing awareness about the research applications of particle therapy systems, development of cost-effective and technologically advanced diagnostic and therapeutic particle therapy systems, and increasing industry-academia collaborations in the field of research are the key factors driving the growth of this segment.
Asia Pacific to dominate the Particle Therapy Market during the forecast period
The Particle Therapy Market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific region is expected to account for the largest share of the global Particle Therapy Market in 2018, and this trend is expected to continue during the forecast period. The Asia Pacific region is expected to offer significant growth opportunities for players operating in the Particle Therapy Market owing to the increasing healthcare expenditure and growing initiatives to promote the use of advanced particle therapy technologies in Asia Pacific countries.
The major players operating in the Particle Therapy Market are Ion Beam Applications SA (Belgium), Varian Medical Systems, Inc. (US), Hitachi, Ltd. (Japan), Provision Healthcare (US), Mevion Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), ProTom International, Inc. (US), Advanced Oncotherapy plc (UK), and Danfysik A/S (Denmark).
Browse Adjacent Markets @ Medical Devices Market Research Reports & Consulting
Radiotherapy Market by Product (LINAC, CyberKnife, Gamma Knife, Tomotherapy, Particle Therapy, Cyclotron), Procedure (External (IMRT, IGRT, 3D-CRT) Internal (LDR, HDR)), Application (Prostate, Breast, Lung), End User (Hospitals) – Global Forecasts to 2026
Patient Positioning System Market by Product (Tables (Surgical Tables, Radiolucent Imaging Tables), Accessories), Application (Surgery, Cancer Therapy, Disease Diagnosis), and End User (Hospitals, Ambulatory Surgery Center) – Global Forecast to 2022
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
7 Comments
Suggested
Recent
🍓 R­a­­­t­­e­ ­­m­­­y­­­ ­­­s­e­­­x­­­y­­ ­­a­­­s­­­s­ 👉 http://foto0965924.sexplay.us
🍓 R­­a­t­­­e­­ ­­m­­­y­ ­­­s­­e­­­x­­­y­­­ ­­a­­­s­­­s­ 👉 http://foto0843779.sexplay.us
🍓 R­­a­t­e­­ ­m­­y­ ­­­s­e­­­x­­y­­­ ­­­a­­­s­s­­­ 👉 http://foto0545695.sexplay.us
🍓 R­­a­­t­e­­­ ­­­m­­y­­ ­­­s­­­e­­x­­­y­ ­­a­s­­s­ 👉 http://foto0851210.sexplay.us
🍓 R­­a­t­­e­­ ­­m­­­y­­ ­s­­­e­x­y­­ ­­a­s­s­ 👉 http://foto0328745.sexplay.us
Cards you may also be interested in
Protein Engineering : Future, Trends, And Scope
The growth of this market is majorly driven by factors such as the increasing investments in synthetic biology and the growing focus on protein-based drug development by pharmaceutical and biotechnology companies.  The rational protein design segment accounted for the largest share of the market in 2019. The large share of this segment can be attributed to the increasing use and continuous upgrades of bioinformatics platforms and software for protein analysis.  The global market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the global market, closely followed by Europe.  Factors such as the presence of well-established CROs, rising R&D expenditure, and the availability of the latest techniques and instruments for drug discovery research are responsible for the large share of the North American market. However, the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=898  Monoclonal antibodies accounted for the largest share of the protein engineering market in 2019, majorly due to the high and growing demand for monoclonal antibodies for the treatment of cancer, neurological diseases, and infectious diseases.  The rational protein design segment accounted for the largest share of the market, majorly due to the increasing use and continuous upgrades of bioinformatics platforms and software for protein analysis.  The protein engineering market is segmented into biopharmaceutical companies, contract research organizations, and academic research institutes. Biopharmaceutical companies use protein engineering products extensively in their drug discovery and development activities as these products help in designing models to develop a broad range of protein-based drugs. As a result, biopharmaceutical companies were the largest end-users in this market in 2019.  The major companies operating in the global protein engineering market include Thermo Fisher Scientific (US), Danaher Corporation (US), Agilent Technologies (US), and Bio-Rad Laboratories (US).  Market Research Developments: In 2019, Creative Biolabs (US) launched the cd25 monoclonal antibody. In 2019, Waters Corporation (US) launched Vanguard FIT Cartridge Technology. In 2019, Agilent Technologies (US) acquired BioTek Instruments (US), which helped the company to expand its expertise in cell analysis and establish its position in the immuno-oncology and immunotherapy markets. In 2019, Merck KGaA signed a license agreement with Amunix Pharmaceuticals, Inc. (US). Under this agreement, Amunix will gain the rights to develop therapeutics using the protease-triggered immune activator (ProTIA) technology platform.
Order Xanax online for Anxiety and panic attacks
order now with 20% discount >>>https://onlinehealths.com/product-category/buy-xanax-online/(hurry up) Order Xanax online medicine uses to treat Anxiety and panic attacks related disorders. But before consumption of this medicine, first of all you will have to know about all the information about how many doses are right for use and how the type of this medicine can be effective, otherwise, you will put yourself in trouble because of incorrect use. Does teladoc prescribe Xanax? Teladoc therapists do not prescribe medications. What is the most Xanax a doctor can prescribe? When you suffer from these Anxiety and panic disorders problems. So, your doctor can be prescribes for the consumption of this medicine. In starting you can take Xanax 0.25 mg, Xanax 0.5 mg tablet medicine and after some time may your doctor will increase slowly some dose. But does not usually exceed more than 4 mg of medicine. Can you get Xanax from urgent care? Can you get Xanax over the counter in the USA? If you want to purchase Xanax medicine. Then a good opportunity is available in front of you. The medicine is easily available over the counter. And in your general stores. But if you would not like to go outside from your home and also, you want to get your medicine at your home. Then you can order Xanax online medicine. Because there are more trustworthy websites available for you. They provide you with all the medicines overnight delivery at your home. Can doctors on demand prescribe anxiety meds? Yes, Xanax 0.5 mg tablet medicine’s more in demand by doctors. Because Xanax medicine treats anxiety and panic disorder rapid relief, and most doctors suggest their patients for their consumption of this medicine. Will doctors prescribe Xanax long-term? In rare cases, doctors prescribe you this medicine for a long time. If your doctor prescribes for a long time. So, according to your doctor, you should follow your dose and diet and all must take all the precautions. Why is Xanax being taken off the market? What works better than Xanax? Xanax medicine is available in the general store. But not easily available in the market then you can buy Xanax online from the USA’s worthy websites. Klonopin medicines are more effective than Xanax medicine. Does Klonopin feel like Xanax? Klonopin medicine is more addictive than Xanax medicine. Klonopin medicine produces more feelings of euphoria. What is the generic version of Xanax? The generic name of Xanax medicine is Alprazolam. It is uses to treat anxiety and panic disorders related problems. If you seem like you are having this problem. So, you should immediately consult your doctor for the treatment on time. Conclusion I hope you will understand about Xanax medicine. Also, if you are bearing anxiety and panic attacks. So, in this condition, the consumption of Xanax medicine can be very effective. Also, you should order Xanax online from the USA’s trustworthy websites. And the website provides you with Xanax online at overnight delivery at your home. But, I will remind you of that. Before taking this medicine you should take consultation from your doctor for the right treatment by which you can get fast relief in your problem.
Is it worth using Prozac (fluoxetine) as an antidepressant? Find out More!
Prozac is an antidepressant. It's also known as fluoxetine, which is its generic name. Prozac (fluoxetine) is efficient in improving your state of mind, energy levels, sleep, and appetite. This medication is likewise valuable in lessening fear, undesirable considerations, and tension. Prozac (Fluoxetine) is readily accessible as a liquid, tablet, capsule, and long-acting capsule with delayed release. It is advisable for grown-ups and can sometimes be used for children aged 10 years and older. What is Prozac (Fluoxetine) used for? Prozac (Fluoxetine) is an FDA-approved medication. It has been used to treat major depressive disorder (in people aged eight and up), panic attacks, eating disorders (bulimia and binge-eating disorders), bipolar disorder, and premenstrual dysphoric disorder. For treatment-restricted depression, Prozac (Fluoxetine) is also used in conjunction with olanzapine. Prozac (fluoxetine) non-FDA-authorized applications incorporate social anxiety disorder (also known as social phobia), borderline personality disorder, post-traumatic stress disorder, Raynaud phenomenon, and selective mutism. Is Prozac (Fluoxetine) an SSRI? Prozac (Fluoxetine) belongs to the selective serotonin reuptake inhibitors (SSRIs) class of antidepressants. Selective serotonin reuptake inhibitors (SSRIs) are considered "selective" because of their little impact on dopamine or norepinephrine. They exert their therapeutic effect by inhibiting serotonin reuptake. Prozac (fluoxetine) was the first SSRI to be sold in the United States. It has received significant interest among the press and has reduced the long-term stigma and dread of using antidepressants. Over 100 million individuals globally take selective serotonin reuptake inhibitors (SSRIs). One in ten people in the US and one in four women between 40 and 50 years old is supposed to take SSRI to improve their moods by enhancing their brain serotonin. What Does Prozac (Fluoxetine) Do These medications are supposed to operate by boosting serotonin levels, a mood-enhancing neurotransmitter in the brain. These drugs increase the accessibility of serotonin at synapses (associations between brain cells known as neurons) by forestalling the reuptake of serotonin by neurons. How Long Does it Take For Prozac (Fluoxetine) to work Because of its long half-life (4 to 6 days), the initial impact arises within two weeks to about a month. You'll likely continue to take Fluoxetine (Prozac) for several months after you feel better. Most specialists suggest you take antidepressants for a half year to a year after you presently don't feel depressed. Halting before that time can make anxiety return. Prozac (Fluoxetine) Dosage Peruse the medication guide given by your drug specialist before you use Prozac (Fluoxetine) and, each time, you get a top-up. If you have any inquiries, ask your primary care physician or drug specialist before taking this medication. The Prozac (Fluoxetine) dosage is determined by the patient's age and the treatment's goal. The average adult dose of Prozac (Fluoxetine) is 20 milligrams, given by mouth once daily in the morning. If the symptoms do not improve after a few weeks, specialists can increase the dose up to 60 mg. Geriatric or patients with co-morbidities may need to take Fluoxetine (Prozac) at a lesser dose or less frequently. The maintenance dose of Prozac (Fluoxetine) is 20-60 mg per day, while the highest dose is 80 mg. If you are using this medication twice a day, your doctor may tell you to take it once in the morning and then again in the afternoon. An individual who is taking a delayed-release oral capsule to treat depression will take once a 90 mg delayed-release oral capsule a week. If you're taking Prozac (Fluoxetine) in liquid form, use special measuring equipment to make sure you get the proper dose. Use a measuring spoon instead of a household spoon to ensure you get the right dose. What Should I Do If I Miss A Dose Of Prozac (Fluoxetine)? On the off chance that you sometimes neglect to take a dose, don't stress. Take your next dose the following day at the typical time. Never take two doses simultaneously to compensate for a failed to remember one. Prozac (Fluoxetine) Side Effects Prozac (Fluoxetine), like all drugs, can lead to negative consequences in some people, although many people experience no or moderate side effects. As your body adjusts to Fluoxetine (Prozac), many of the most typical harmful effects will fade away. Headaches, anxiety, insomnia, nausea, stomach discomfort, dry mouth, sleepiness, dizziness, trembling, yawning, lethargy, exhaustion, agitation, reduced sexual desire, difficulty or inability to climax, and ejaculation problems are all common side effects of Prozac (Fluoxetine). Joint discomfort, swelling of the face, tongue, and lips, QT prolongation, convulsions, glaucoma, redness of the eye, irregular heartbeat, breathing problems (dyspnea), and serotonin syndrome are all serious but rare side effects of Prozac (Fluoxetine). Prozac (Fluoxetine) Drug-Drug Interactions Medicines that cause bleeding, bruising, or act as blood thinners may react with Prozac (fluoxetine) including, antiplatelet drugs and warfarin. Taking MAO (monoamine oxidase inhibitors) alongside this prescription could cause a dangerous (potentially fatal) drug interaction. Patients should avoid MAO inhibitors for at least two weeks before and after Prozac (fluoxetine) treatment. When to begin or stop using this medicine, consult your doctor. For medicines that affect your heart rate, avoid taking Prozac (Fluoxetine) with them. It may interact with the medication and cause an elevated or abnormal heart rate. Antipsychotics, other SSRIs, and serotonergic drugs like lithium and St. John's Wort should not be combined with Prozac (Fluoxetine). They may cause severe drug-drug interactions. Prozac (Fluoxetine) In Pregnancy And Breastfeeding Prozac (Fluoxetine) transfers to the breast milk in a moderate amount. There is a low risk of harm to the infant according to the limited data available. The general recommendation however is to avoid unless necessary during lactation. It's significant for you and your child that you stay well during your pregnancy. If you become pregnant while taking Prozac (Fluoxetine), address your primary care physician. Try not to quit taking your medication except if your PCP advises you to. Experts have associated Prozac (Fluoxetine) with a modest increase in the chance of complications for your potential child. However, if you don't get help for your depression while you are pregnant, you're more likely to have issues. Offer your significant criticism with us on the off chance that you discover this subject instructive and need to study drugs used in emotional wellbeing. Or, if you are experiencing any mental health disorders, counsel our organization as it's anything but a group of specialists, clinicians, and advisors to take care of you.
Fast, Affordable and Aesthetic 3D-printed Dental Restorations: Research News
The dental 3D printing medical devices market is primarily driven by factors such as the high incidence of dental caries and other dental diseases, rising demand for cosmetic dentistry, the growing adoption of dental 3D printers in hospitals and clinics, and rapid growth in the geriatric population.   In the optimistic scenario, it could be assumed that the COVID-19 pandemic would create a long-term positive impact on the overall dental 3D printing market. The dental 3D printing market was initially negatively impacted by the COVID-19 pandemic, as most dental offices, clinics, and laboratories were closed in many parts of the world due to lockdowns and quarantine restrictions in early 2020.   In an optimistic scenario, the need for smoother clinical workflows, faster turnaround times, and fewer dental appointments could boost the market growth. Dentists may be more likely to invest in technologies like CAD/CAM and dental 3D printing to reduce the time taken to deliver dental appliances and treatment, and patients may be more likely to opt for these solutions for the same reason.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=258228239 Dental caries or tooth decay is a common ailment across all age groups, with the global incidence of decayed and missing teeth (DMT) increasing dramatically in recent years. According to the CDC, in 2019, 64.9% of adults aged above 18 years of age had a dental examination or dental cleaning procedure.   According to the American College of Prosthodontists, more than 36 million Americans are completely edentulous, and around 120 million Americans are missing at least one tooth. As dental implants, dental prosthetics, and other dental products manufactured by dental 3D printers find high use in the restoration of the dental structure, the high incidence of target diseases will play a key role in the growth of the dental 3D printing.    There is a very limited resource pool available for staff that is well-versed with 3D printing processes, which is further worsened by the rapid pace of evolution of the dental 3D printing market in terms of technology and materials. There is a dearth of training programs available for additive manufacturing and a wide gap between academia and practical applications in the industry that is difficult to bridge. The lack of a well-qualified workforce would restrain the overall adoption of dental 3D printing.  Key players in the Dental 3D Printing market: The prominent players in the global dental 3D printing market include Stratasys Ltd. (US), 3D Systems, Inc. (US), EnvisionTEC (Germany), DWS Systems SRL (Italy), Renishaw (UK), Formlabs (US), Prodways Group (France), SLM Solutions Group AG (Germany), Carbon, Inc. (US), Concept Laser (Germany), EOS GmbH Electro Optical Systems (Germany), Rapid Shape (Germany), Asiga (Australia), Roland DG (Japan), DENTSPLY Sirona, Inc. (US), SprintRay (US)
Growth Opportunity, Regional Insights, Competitive Outlook For Microbial Identification
Growth in this market is largely driven by the rising incidence of infectious diseases and the increasing frequency of pandemics, technological advancements, increasing food safety concerns, and increasing government initiatives and funding to detect and control antimicrobial-resistant species.  COVID-19 Impact On The Global Microbial Identification Market According to a study conducted by ClinicalTrials.gov, to prevent screening shortages, an innovative PCR-free alternative strategy was developed based on the detection of specific protein signatures in human saliva by MALDI-TOF MS profiling. MALDI-TOF MS profiling is a method used in routine diagnostics by microbiology laboratories for the identification of microorganisms. MALDI-TOF MS profiling has been successfully used to classify individuals according to their infectious status based on the analysis of their saliva.  It is also used as a tool for the identification of respiratory viruses from cell culture supernatants. MALDI-TOF MS is one of the major technologies used in microbial identification. The COVID-19 pandemic has had a major impact on the US, China, India, as well as many major European countries. Since most of these countries are major manufacturers of the instruments and consumables used for microbial identification, the pandemic and nationwide lockdowns have caused a decline in the sales of these products.   Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=10702182 Microbial identification is mainly used for human disease diagnosis. It delivers rapid and reliable results that help in the timely adoption of appropriate therapies. Microbial identification products can improve the management of infectious diseases, especially in areas with inadequate healthcare infrastructure. It is estimated that approximately 1,400 pathogens can cause human diseases.   Pathogenic bacteria alone cause about 350 million cases of foodborne diseases. About 48 million foodborne illnesses occur annually in the US alone, which leads to approximately 128,000 hospitalizations and 3,000 deaths every year. Poor water hygiene can cause 1.7 million deaths a year worldwide, and 9 out of 10 deaths occur in children. Most of these deaths, however, are observed in developing countries (NCBI). Over the years, there has been a significant increase in the prevalence of infectious diseases worldwide. According to the WHO, TB is one of the top 10 causes of death. A total of 1.5 million people died from TB in 2018 worldwide. Between 2000–2018, an estimated 58 million lives were saved through TB diagnosis and treatment. ccording to the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2019, globally, 1.7 million people were newly infected with HIV, 38 million people are living with HIV, and 690,000 people died of AIDS-related illnesses. Furthermore, incidents such as the Zika epidemic (2016), Ebola epidemic (2014), H1N1 swine flu pandemic (2009), H5N1 Avian flu pandemic (2004), Severe Acute Respiratory Syndrome (SARS) pandemic (2003), and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic (2019–2020) have caused serious health concerns. They also lead to an increased demand for diagnostic products, including those for microbial identification. Thus, the high prevalence and incidence of different infectious diseases, coupled with the increasing frequency of pandemics, are driving growth in the microbial identification market.  Some of the leading players in the microbial identification market include bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Bruker Corporation (US), Shimadzu Corporation (Japan), QIAGEN NV (Netherlands), Avantor, Inc. (US), and Biolog, Inc. (US).  The phenotypic methods segment accounted for the largest share of the microbial identification market in 2019. The large share of this segment can be attributed to the wide usage of phenotypic methods for microbial identification across the healthcare, food & beverage, pharmaceutical, and environmental sectors
Without Conviction Animal-Cruelty Case To End: Animal Treatment
The growth of the animal treatment market can be attributed to increasing government initiatives, which ensure maximum preventive healthcare for animals. A majority of the developed economies have norms that impel owners to have pet insurance.  By animal type, the horse's segment is expected to register the highest growth rate during the forecast period. Based on animal type, the animal treatment market is segmented into dogs, cats, horses, cattle, pigs, and poultry. The percentage of medical treatment received by horses is predicted to grow by 2024. In several countries, racehorses are considered to be of economic importance. Therefore, it becomes imperative for caretakers to provide maximum preventive as well as long-term veterinary care to equine species, as negligence pertaining to equine species may have an economic impact. On average, over 70-75% of the horses receive maximum preventive healthcare.  By treatment type, the veterinary care segment is expected to register the highest growth rate in the forecast period. Based on treatment type, the animal treatment market is segmented into no medicalization, basic medicalization, and veterinary care. Over the years, the demand for veterinary care services has increased. Veterinary clinics and hospitals in developed as well as developing countries are well-equipped with the necessary equipment for diagnosis and treatment. For instance, Banfield Hospital in the US is one of the most sophisticated hospitals that provides diagnostic tests for animals. North America is the largest market for animal treatment North America is the largest market in terms of the consumption of veterinary products. People are well versed with animal healthcare regulations, and hence high-quality care is provided to animals in this region.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180479252  However, the animal treatment market has become saturated in the US, as the number of veterinary visits has stabilized. On the contrary, the animal treatment rate in European countries has increased. The increasing standard of living and the growing number of veterinarians providing exceptional medical services to animals are the major factors driving the European animal treatment market. Prominent players in the animal treatment market are Zoetis (US), Merck (US), Boehringer Ingelheim (Germany), Elanco (US), Ceva (France), Phibro Animal Health Corporation (US), Abaxis (US), Virbac SA (France), IDEXX Laboratories, Inc. (US), Neogen Corporation (US), and Heska Corporation (US).
Particle Therapy Market worth USD 1,349 million by 2023 : Technological advancements in the field of Heavy Ion Therapy
The study involved four major activities to estimate the current market size for particle therapy. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter market breakdown and data triangulation was used to estimate the market size of segments and subsegments. According to the new market research report “Particle Therapy Market by Type (Heavy Ion, Proton Therapy), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate, Breast), Application (Treatment, Research) – Forecast to 2023“, published by MarketsandMarkets™, the global Particle Therapy Market is projected to reach USD 1,349 million by 2023 from USD 865 million in 2018, at a CAGR of 9.3%. Browse in-depth TOC on “Particle Therapy Market“ 80 – Tables 36 – Figures 138 – Pages Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12809137 The major factors driving the growth of the Particle Therapy Market are the growing global prevalence of cancer, growing adoption of particle therapy in clinical trials, advantages offered by particle therapy over photon therapy, and the increasing number of particle therapy centers worldwide. The pediatric cancer segment is expected to account for the largest share of the Particle Therapy Market, by cancer type, in 2018 Based on cancer type, the Particle Therapy Market is segmented into pediatric cancer, prostate cancer, breast cancer, lung cancer, head & neck cancer, and other cancers. The pediatric cancer segment is expected to account for the largest share of the Particle Therapy Market in 2018. The growing incidence of pediatric cancer and the high success rates and minimal long-term risks achieved with particle therapy are the major factors driving the growth of this market segment. Research applications to register the highest CAGR in the global Particle Therapy Market during the forecast period Based on applications, the Particle Therapy Market is segmented into treatment applications and research applications. The research applications segment is expected to witness the highest CAGR during the forecast period. Growing awareness about the research applications of particle therapy systems, development of cost-effective and technologically advanced diagnostic and therapeutic particle therapy systems, and increasing industry-academia collaborations in the field of research are the key factors driving the growth of this segment. Asia Pacific to dominate the Particle Therapy Market during the forecast period The Particle Therapy Market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific region is expected to account for the largest share of the global Particle Therapy Market in 2018, and this trend is expected to continue during the forecast period. The Asia Pacific region is expected to offer significant growth opportunities for players operating in the Particle Therapy Market owing to the increasing healthcare expenditure and growing initiatives to promote the use of advanced particle therapy technologies in Asia Pacific countries. Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=12809137 The major players operating in the Particle Therapy Market are Ion Beam Applications SA (Belgium), Varian Medical Systems, Inc. (US), Hitachi, Ltd. (Japan), Provision Healthcare (US), Mevion Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), ProTom International, Inc. (US), Advanced Oncotherapy plc (UK), and Danfysik A/S (Denmark). Browse Adjacent Markets @ Medical Devices Market Research Reports & Consulting Radiotherapy Market by Product (LINAC, CyberKnife, Gamma Knife, Tomotherapy, Particle Therapy, Cyclotron), Procedure (External (IMRT, IGRT, 3D-CRT) Internal (LDR, HDR)), Application (Prostate, Breast, Lung), End User (Hospitals) – Global Forecasts to 2026 https://www.marketsandmarkets.com/Market-Reports/radiotherapy-monitoring-devices-market-567.html Patient Positioning System Market by Product (Tables (Surgical Tables, Radiolucent Imaging Tables), Accessories), Application (Surgery, Cancer Therapy, Disease Diagnosis), and End User (Hospitals, Ambulatory Surgery Center) – Global Forecast to 2022 https://www.marketsandmarkets.com/Market-Reports/patient-positioning-system-market-12586699.html About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Research Insight: https://www.marketsandmarkets.com/ResearchInsight/particle-therapy-market.asp
Bioprocess Containers expected to register a CAGR of 26.3% during 2021-2026
Growth in the bioprocess containers market is mainly driven by factors such as the growing biologics market, affordability and sustainability of single-use bioprocess technologies, and rising biopharmaceutical R&D. Emerging countries and the patent expiry of biologics are expected to offer growth opportunities for players operating in the bioprocess containers market during the forecast period.  COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has since moved from being a regional crisis to a global pandemic.  Since most of the leading COVID-19 vaccine programs are using novel approaches, including mRNA, DNA vaccine, and vectors, these platforms are largely built on single-use technology. Most of the pandemic-related new facilities are largely engaging single-use systems due to their flexibility combined with high speed and much lower capital investment compared to traditional stainless steel equipment. The 2D bioprocess containers segment accounted for the largest share of the type segment in the bioprocess containers market in 2020. On the basis of type, the bioprocess containers market is segmented into 2D bioprocess containers, 3D bioprocess containers, and other containers and accessories. In 2020, the 2D bioprocess containers segment accounted for the largest share of the bioprocess containers market. 2D bioprocess containers are frequently used in cell harvesting and for the transportation of bulk drug products and bulk drug precursors.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107645832 The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the end user segment in the bioprocess containers market in 2020. On the basis of end user, the bioprocess containers market is segmented into pharmaceutical & biopharmaceutical companies, CROs & CMOs, and academic & research institutes. In 2020, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the bioprocess containers market. The demand for biopharmaceuticals among the senior population is increasing as the elderly are more prone to various diseases/disorders that can be treated using biologics.  The growth of single-use technologies can be attributed to the growing need for better, cheaper, and faster biologics production. Active development of individualized biologics and personalized medicines, including patient-specific cellular & gene therapies and therapeutic vaccines, demands high sterility and is therefore manufactured using single-use equipment and consumables.  In 2020, the US FDA approved 53 new medicines and therapeutic biologics (Source: US FDA). Growth in the biologics market is mainly driven by monoclonal antibodies and human insulin, which are among the leading contributors to the bioprocess containers market.  Additionally, the Centre for Biologics Evaluation and Research’s (CBER) (2021-25) strategic plan involves various schemes for boosting the growth of the biologics market. With increasing growth in the biologics market, the number of bioprocess containers needed for R&D and biologics manufacturing is also expected to increase in the coming years.  Request For Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=107645832 Extractables are compounds that can be extracted from source materials using appropriate solvents under vigorous laboratory conditions, while leachables are compounds present in drug products caused by leaching from containers, closures, and processing components. Therefore, leachables can be considered a subset of extractables.  Extractables and leachables are commonly associated with polymeric and elastomeric materials due to the use of additives to increase stability and aid in the formation of material components.  According to a survey conducted by BioPlan Associates in 2018, 73.3% of respondents agreed that leachables and extractables are major concerns that may limit the use of bioprocessing in the near future. As single-use assembly products are made of processed plastic materials, they often face the problem of contamination from the container due to leachables.  Some of the leading players operating in the bioprocess containers market are Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US),  Danaher Corporation (US), and Merck Millipore (Germany).
The Future of Cell & Gene Therapy Manufacturing Services - Trends And Analysis
Growth in cell & gene therapy manufacturing services market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs. However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of cell & gene therapy manufacturing services market to a certain extent. According to GEP Worldwide, more than 1,200 clinical trials across the globe were disrupted by June 2020. Nearly 61% of clinical trials were disrupted due to the suspension of patient enrolment. The impact varied due to changes in COVID-19 case volumes throughout the year, but the worst effect was seen in April 2020. Trials involving respiratory disease, oncology, ID/anti-infectives, and cardiovascular disease were the worst-hit during this time. The trend suggests that the top pharma companies are increasing their R&D efficiencies through heavy R&D investments to see returns on their investment in the long run and through collaborative R&D efforts. According to an EvaluatePharma report, the worldwide pharmaceutical R&D spending was valued at USD 136 billion in 2012; this increased to USD 186 billion in 2019. The increase in pharmaceutical R&D has resulted in a sharp increase in the number of cell & gene therapy candidates under development. This has made it necessary to outsource manufacturing services to develop cost-effective and efficient cell & gene therapies For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180609441 Most viral vectors are produced using adherent manufacturing, which is expensive to operate—a vial of 20 million cells can cost USD 20,000 to USD 30,000 to make. The cost of manufacturing for gene therapy can be between USD 500,000 and USD 1 million, excluding the costs for R&D, the costs to run crucial clinical trials, or the costs to build the commercial infrastructure necessary to provide access to patients. According to a 2020 PhRMA report on the cell & gene therapy pipeline in 2018, there were 289 cell & gene therapies in clinical development by biopharmaceutical companies. This number increased by 25% in 2020, with 362 cell & gene therapies in clinical development. In addition to this, according to data released by CGT Catapult, there were 154 ATMP clinical trials ongoing in the UK in 2020 compared to the 127 trials reported in 2019, indicating an increase of more than 20%.  
Injection Trays Market by Competitive Landscape, SWOT Analysis, Opportunities and Challenges, Growth by 2021-2028
Injection trays market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to grow at a CAGR of 7.40% in the above-mentioned forecast period. The growing awareness among the patients regarding the availability of injection trays which will further create lucrative opportunities for the growth of the market. Request Sample Copy @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-injection-trays-market Rising demand of eco-friendly, lightweight, durable and recyclable material, prevalence of improved distribution channels, increasing application of trays during transportation and displaying product, easy availability of trays in pharmacies which will likely to enhance the growth of the injection trays market in the forecast period of 2020-2027. On the other hand, increasing innovation in product designing which will further bring various opportunities for the growth of the injection trays market in the above mentioned forecast period. Global Injection Trays Market Scope and Market Size Injection trays market is segmented on the basis of type, material and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications. Based on type, injection trays market is segmented into hard, and soft. On the basis of material, injection trays market is segmented into polyethylene terephthalate (PET), PETG (polyethylene terephthalate with glycol), RPET (recycled polyethylene terephthalate), polyvinyl chloride, high density polyethylene (HDPE), polypropylene, and others. Injection trays market has also been segmented based on the end user into hospitals, ambulatory surgical centres, speciality clinic, and others. Request for TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-injection-trays-market Injection Trays Market Country Level Analysis Injection trays market is analysed and market size insights and trends are provided by country, type, material and end user as referenced above. The countries covered in the injection trays market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. Inquiry Before buy @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injection-trays-market Competitive Landscape and Injection Trays Market Share Analysis Injection trays market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to injection trays market. The major players covered in the injection trays market report are Krinsha Industries (Dedhia Group), AVA PACKAGING, Shanghai Leenol Industrial Co., Ltd., Hebei Shuangli Packaging Products Co., Ltd., Europack, Insulink Packaging Solutions Pvt. Ltd., Jal Extrusion Private Limited., Vinpac Innovations., Vintec Industries., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.